Tilray: From Seed to Sale - The Cannabis Supply Chain Revolution

Cannabis grows like any other plant, but it is regulated like a pharmaceutical, and that gap between how it's grown and how it must be handled is what makes its supply chain genuinely hard to manage. This case study, built for a supply chain management course, examines how Tilray built a "seed to sale" strategy that treats cannabis with the same rigor as regulated medicine, and how that strategy compares to its main competitors.

What "seed to sale" actually means

The core idea behind Tilray's strategy is full vertical control, from cultivation through to the point of sale. Because cannabis functions as medicine in many of its markets, it has to be tested, packaged, and regulated like one rather than treated as an ordinary agricultural crop. Every stage of the process has to be verified, and compliance isn't treated as optional; it's described as essential to the whole operation. That standard shows up concretely in GMP, Good Manufacturing Practice, which the case study calls the gold standard for the industry. Meeting it is expensive, but Tilray tracks potency, purity, and transparency at every step regardless of the cost, because those checks are what let the product move across borders that each carry different laws.

Adapting to geography instead of fighting it

Tilray's approach to location is a case study in working with constraints rather than around them. Canada is cold and not ideal for growing cannabis, but it's where the company began, using greenhouses to cover the climatic gap. Rather than trying to force production into one location, Tilray grows where conditions are warm and processes closer to where it sells, an approach the case study frames as smart adaptation to both climate and shifting regulation. As laws change, often shaped by lawmakers who are still working out how to regulate the industry, Tilray positions itself as a company that helps shape those rules rather than simply reacting to them after the fact.

Diversification as a hedge

Beyond cannabis itself, Tilray has expanded into wellness drinks, lifestyle brands, and notably craft beer, building strong regional brands to weather regulatory and market volatility. In 2022, the company acquired eight beer brands from Anheuser-Busch and four craft brands from Molson Coors, moves that made Tilray the fifth largest craft beer company in the United States. In July 2024, it won a major German cultivation license, expanding its footprint in a market where post-2024 reforms reportedly expanded licensing capacity fivefold, positioning Tilray to supply a market of over 13,000 pharmacies. Its German operation, described as an Africa RX farm-grade facility, is aimed at avoiding import barriers through local cultivation, while in Canada, its Africa 1 and Diamond facilities are set to produce roughly two metric tons, with outdoor grows beginning in spring 2025 and surplus inventory earmarked for export to high-margin markets.

How Tilray stacks up against competitors

The case study places Tilray against three named rivals, each representing a different supply chain philosophy. Canopy is betting on the US market through its Canopy USA structure, with partners including Acreage, Wana, and Jetty Extracts. Aurora runs a hybrid model, mixing in-house cultivation with third-party growers, and its international revenue has reportedly surpassed its Canadian medical sales. Curaleaf is US-centric, running dispensaries from seed to sale through 19 grow sites, giving it a strong urban stronghold but limited global reach. Cronos, by contrast, relies on partners to grow its product, which saves on overhead but sacrifices control, and the case study notes that this approach led to supply disruptions in 2025.

Against those approaches, Tilray's stated advantages are global scale, cultivating at a reported 247 metric tons annually, a diversified portfolio beyond cannabis, and flexible operations that can adapt to shifting demand. The trade-off is real: regulatory complexity, expensive logistics, legal uncertainty, and the sheer cost of vertical integration are called out explicitly as the price of that control.

What's next, including an unused tool

The case study also points to blockchain as a capability Tilray doesn't currently use but could apply to verify every step of its supply chain, optimizing tracking, certification, and trust between growers, scientists, and the market. As of the case study, the company is positioned as ready for both the US and EU markets, but still waiting on regulatory gates neither it nor its competitors control.

Key takeaways

• Tilray's seed to sale strategy is built on full vertical control and pharmaceutical-grade compliance (GMP), not just agricultural production.
• The company grows where climate is favorable and processes near its sales markets, adapting geography to constraints rather than fighting them.
• Craft beer acquisitions from Anheuser-Busch and Molson Coors diversify revenue and make Tilray the fifth largest US craft beer company.
• Compared to Canopy, Aurora, Curaleaf, and Cronos, Tilray's differentiator is combining global scale with a diversified, non-cannabis product portfolio.
• Vertical integration is powerful but costly, and the company remains dependent on regulatory decisions it cannot control, particularly around US federal legalization.

Who this is for

This case study, developed for Northeastern University's D'Amore-McKim School of Business SCHM 6201 Operations and Supply Chain Management course, is aimed at business students, supply chain professionals, and anyone interested in how vertical integration strategies play out in a heavily regulated, emerging industry.